Peut-on prévoir l'hormono-résistance d'un cancer de prostate à partir de la biopsie initiale?

: We present 271 prostatic adenocarcinomas with a follow-up of between 11.5 and 18 years, treated by palliative hormone therapy. Multivariate analysis defines three groups. Group 1 (78 cases): with a normal survival; Groups II and III: with poor survival. In this group, treatment is ineffective.